
SUBSTANTIAL SHAREHOLDERS

SUBSTANTIAL SHAREHOLDERS

So far as our Directors are aware, immediately following the completion of the Global Offering and assuming the Over-allotment Option is not exercised and no shares are issued pursuant to the Equity Plans, the following persons (other than a Director or chief executive of the Company) will have interests and/or short positions (as applicable) in the Shares or underlying shares of our Company which would fall to be disclosed to the Company and the Stock Exchange pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or, will be, directly or indirectly, interested in 10% or more of the nominal value of any class of our share capital carrying rights to vote in all circumstances at general meetings of our Company or any other member of our Group:

Name of substantial shareholder	Capacity/ Nature of Interest	Number of shares held	Approximate percentage of shareholding in our Company after completion of the Global Offering
Asia Ventures ⁽¹⁾	Beneficial interest	78,122,780	6.99%
Asia Partners II L.P. ⁽¹⁾	Interest in a controlled corporation	78,122,780	6.99%
FIL Capital Management Ltd ⁽¹⁾	Interest in a controlled corporation	78,122,780	6.99%
FIL Limited ⁽¹⁾	Interest in a controlled corporation	156,245,560	13.97%
Pandanus Partners L.P. ⁽¹⁾	Interest in a controlled corporation	156,245,560	13.97%
Pandanus Associates Inc. ⁽¹⁾	Interest in a controlled corporation	156,245,560	13.97%
F-Prime Capital ⁽²⁾	Beneficial interest	78,122,780	6.99%
F-Prime Capital Partners Healthcare Advisors Fund II LP ⁽²⁾	Interest in a controlled corporation	78,122,780	6.99%
Impresa Fund III Limited Partnership ⁽²⁾	Interest in a controlled corporation	156,245,560	13.97%

SUBSTANTIAL SHAREHOLDERS

Name of substantial shareholder	Capacity/ Nature of Interest	Number of shares held	Approximate percentage of shareholding in our Company after completion of the Global Offering
Impresa Management LLC ⁽²⁾	Interest in a controlled corporation	156,245,560	13.97%
Abigail P. Johnson ⁽²⁾	Trustee	156,245,560	13.97%
Edward C. Johnson IV ⁽²⁾	Trustee	156,245,560	13.97%
FMR LLC ⁽²⁾	Interest in a controlled corporation	156,245,560	13.97%
Seacliff (Cayman) Ltd. ⁽³⁾	Beneficial interest	65,769,750	5.88%
Capital International Private Equity Fund VI, L.P. ⁽³⁾	Interest in a controlled corporation	65,769,750	5.88%
Capital International Investments VI, L.P. ⁽³⁾	Interest in a controlled corporation	65,769,750	5.88%
Capital International Investments VI Limited ⁽³⁾	Interest in a controlled corporation	67,064,090	6.00%
TLS Beta ⁽⁴⁾	Beneficial interest	64,482,850	5.77%
Temasek Life Sciences Private Limited ⁽⁴⁾	Interest in a controlled corporation	64,482,850	5.77%
Fullerton Management Pte Ltd ⁽⁴⁾	Interest in a controlled corporation	64,482,850	5.77%
Temasek Holdings (Private) Limited ⁽⁴⁾	Interest in a controlled corporation	64,482,850	5.77%
Great Biono Fortune LP ⁽⁵⁾	Nominee shareholder	90,100,040	8.06%
Great Biono Fortune Limited ⁽⁵⁾	Interest in a controlled corporation	90,100,040	8.06%
De-Chao Michael Yu ⁽⁵⁾⁽⁶⁾	Beneficial owner	45,628,190	4.08%
	Grantor of a trust	10,000,000	0.89%
	Interest in a controlled corporation	90,100,040	8.06%

SUBSTANTIAL SHAREHOLDERS

Notes:

- (1) FIL Limited is deemed to be interested in the equity interests held by both Asia Ventures and F-Prime Capital, due to (i) its interests in Asia Ventures as a limited partner and the fact that it is the sole shareholder of FIL Capital Management Ltd, the general partner of Asia Partners II L.P., which in turn is the general partner of Asia Ventures; and (ii) its interests in F-Prime Capital as a limited partner. FIL Limited is controlled (as defined under the SFO) by Pandanus Partners L.P., whose general partner is Pandanus Associates Inc..

As such, under the SFO, FIL Capital Management Ltd is deemed to be interested in the 78,122,780 Shares held by Asia Ventures, and FIL Limited, Pandanus Partners L.P., and Pandanus Associates Inc. are deemed to be interested in the 156,245,560 Shares held by Asia Ventures and F-Prime Capital.

- (2) Impresa Fund III Limited Partnership is deemed to be interested in the equity interests held by both Asia Ventures and F-Prime Capital, due to its interests in each of Asia Ventures and F-Prime Capital as a limited partner. The general partner of Impresa Fund III Limited Partnership is Impresa Management LLC, which is controlled (as defined under the SFO) by each of Abigail P. Johnson and Edward C. Johnson IV and owned, directly or indirectly, by various shareholders and employees of FMR LLC. Further, the general partner of F-Prime Capital is F-Prime Capital Partners Healthcare Advisors Fund II LP, whose general partner is Impresa Management LLC.

As such, under the SFO, F-Prime Capital Partners Healthcare Advisors Fund II LP is deemed to be interested in the 78,122,780 Shares held by F-Prime Capital, and Impresa Fund III Limited Partnership, Impresa Management LLC, Abigail P. Johnson, Edward C. Johnson IV and FMR LLC are deemed to be interested in the 156,245,560 Shares held by Asia Ventures and F-Prime Capital.

- (3) Seaclyff (Cayman) Ltd. is wholly-owned by Capital International Private Equity Fund VI, L.P., the general partner of which is Capital International Investments VI, LP, the general partner of which is Capital International Investments Limited. Under the SFO, Capital International Private Equity Fund VI, L.P., Capital International Investments VI, LP and Capital International Investments VI Limited are deemed to be interested in the 65,769,750 Shares held by Seaclyff (Cayman) Ltd. Further, Dwyer (Cayman) Ltd. is 100% owned by CGPE VI, L.P., the general partner of which is Capital International Investments VI Limited. Therefore under the SFO, Capital International Investments VI Limited is also deemed to be interested in the 1,294,340 Shares held by Dwyer (Cayman) Ltd.
- (4) TLS Beta is a wholly-owned subsidiary of Temasek Life Sciences Private Limited, which is in turn a wholly-owned subsidiary of Fullerton Management Pte Ltd, which is in turn a wholly-owned subsidiary of Temasek Holdings (Private) Limited. Under the SFO, Temasek Life Sciences Private Limited, Fullerton Management Pte Ltd and Temasek Holdings (Private) Limited are deemed to be interested in the 64,482,850 Shares held by TLS Beta.
- (5) Includes (1) 45,628,190 Shares held by Dr. Yu and (2) 10,000,000 Shares held by Gloria Bingqinzi Yu as trustee of Yu Tong Family Irrevocable Trust, of which Dr. Yu and his spouse are the grantors. Under the SFO, Dr. Yu is deemed to be interested in these Shares.
- (6) The general partner of Great Biono Fortune LP is Great Biono Fortune Limited, which holds the interests of Great Biono Fortune LP as to 50% as its general partner. Dr. De-Chao Michael Yu is the sole shareholder of Great Biono Fortune Limited and a limited partner of Great Biono Fortune LP. Under the SFO, each of Great Biono Fortune Limited and Dr. Yu is deemed to be interested in the 90,100,040 Shares held by Great Biono Fortune LP. Of the 90,100,040 Shares held by Great Biono Fortune LP, Dr. Yu is beneficially interested in 59,511,000 Shares.

SUBSTANTIAL SHAREHOLDERS

Except as disclosed above, our Directors are not aware of any other person who will, immediately following the completion of the Global Offering (and assuming the Over-allotment Option is not exercised and no shares are issued pursuant to the Equity Plans), have any interest and/or short positions in the Shares or underlying shares of our Company which would fall to be disclosed to the Company pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or, who is, directly or indirectly, interested in 10% or more of the nominal value of any class of our share capital carrying rights to vote in all circumstances at general meetings of our Company. Our Directors are not aware of any arrangement which may at a subsequent date result in a change of control of our Company or any other member of our Group.